NEWARK, Del, March 01, 2023 (GLOBE NEWSWIRE) -- The global migraine treatments market is poised for strong growth in the coming years, driven by increasing awareness of the condition and advances in treatment options. According to a report by Future Market Insights, the global migraine treatments market is expected to grow at a compound annual growth rate (CAGR) of 4% from 2023 to 2033.
The condition is characterized by severe headaches, often accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound, significantly impacting quality of life by interfering with work, social activities, and other daily routines. There have been several advances in migraine treatment in recent years, with new medications and non-pharmacological approaches becoming available. This is expected to drive growth in the migraine treatments market, as patients seek out more effective and better-tolerated treatments.
Not just this, Healthcare spending is increasing in many countries, which is expected to drive demand for migraine treatments. As individuals become more affluent and more willing to spend on healthcare, demand for treatments is likely to increase.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16751
Key Takeaways from the Market Study
- From 2018 to 2022, the migraine treatments market grew at a CAGR of 3%.
- The global migraine treatments market is expected to grow with a 4% CAGR during 2023 to 2033.
- As of 2033, the migraine treatments Market is expected to reach US$ 4.74 Billion.
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 40% market share for the migraine treatments market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering migraine treatments.” says an FMI analyst
Market Competition
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
- In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson's disease.
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16751
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global migraine treatments market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Drug Class, Route of Administration, Treatment, Distribution Channel & Region.
Key Segments Profiled in the Migraine Treatment Industry Survey
Drug Class:
- Zavegepant
- Atogepant
- Zolmitriptan
Route of Administration:
- Oral
- Parenteral
- Nasal Sprays
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Treatment:
- Abortive Medicine
- Preventive Medicine
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
View Complete Report@ https://www.futuremarketinsights.com/reports/migraine-treatment-market
Table of Content
1. Executive Summary | Migraine Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
Buy Now@ https://www.futuremarketinsights.com/checkout/16751
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at Related Reports of Healthcare domain
Peptide Receptor Radionuclide Therapy (PRRT) Market Size: The market is likely to record a strong CAGR of 7.2% during the forecast period. The market is currently valued at US$ 552.08 Million in 2022 and is likely to reach US$ 1,106.50 Million by 2032.
Late Stage Chronic Kidney Disease Therapeutics Market Share: Late stage kidney disease therapeutics market is anticipated to surpass US$ 11.1 Billion in 2027 and forecast to grow at a prolific CAGR of around 11.6% throughout the forecast period
Brain Biomarkers Market Demand: The global brain biomarkers market is anticipated to exhibit growth at a CAGR of 14.3% in the forecast period from 2022 to 2032. It is set to reach US$ 8.3 Billion in 2022 and US$ 11.5 Billion in 2032.
Bruxism Management Market Overview: As per Future Market Insights (FMI), the market is likely to be valued at US$ 10.1 Billion in 2032 and exhibit growth at a CAGR of 6.9% in the forecast period from 2022 to 2032.
Body Contouring Market Outlook: The net worth of the overall market is expected to rise at a CAGR of 6.9% to US$ 11.1 Billion by 2032.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, US, and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
